BeStock  

Neurocrine Biosciences NBIX

US equityMarket cap rank #1096Drug Manufacturers - Specialty & Generic
$150.57 −$6.02 (-3.84%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $150.57 0.00%
Open$156.27
Prev close$156.59
Day range$150.24 – $158.26
Volume1.59M
Market cap$15.24B
P/E (TTM)22.3
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership102.3%-0.89 pts vs. prior quarter
Institutions holding972-3 vs. prior quarter
Insider trades (recent)16 buys / 30 sellsNet selling
Short interest5.81% of floatDays to cover 5.4 · as of 30 Oct 2026
Short-sale volume share15.8%5-day average of daily volume

Short-sale volume as % of daily volume

8%21%33%45%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$1.83M (11 inflow days, 9 outflow days).

Net flow by order size, last 20 sessions

+$11.0MSuper−$12.9MBig+$5.9MMid+$3.5MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 35.2% of shares outstanding.

Largest holders

  • BlackRock14.68%
  • Dodge & Cox5.44%
  • Vanguard Capital Management, LLC5.17%
  • Vanguard Portfolio Management, LLC5.00%
  • J.P. Morgan Asset Management, Inc.4.90%
  • State Street Global Advisors4.75%
  • AQR Capital Management2.99%
  • Vestal Point Capital, LP2.47%

By investor type

  • Mutual Fund78.92%
  • Hedge Fund13.49%
  • Public Company3.46%
  • Government Pension Fund2.64%
  • Private Company1.64%
  • Individual/Insider1.20%
  • Sovereign Wealth Fund1.07%
  • Insurance Company0.33%

Reported short interest has risen from 4.48% to 5.81% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
BlackRock Mutual Fund 2026/Q4 +1,144,496 14.7%
Vestal Point Capital, LP Hedge Fund 2026/Q4 +620,000 2.5%
Thrivent Investment Management, Inc. Mutual Fund 2026/Q4 +526,736 0.8%
Ninety One UK Limited Mutual Fund 2026/Q4 +434,610 0.4%
State Street Global Advisors Mutual Fund 2026/Q4 +422,377 4.8%
KBC Asset Management NV Mutual Fund 2026/Q4 +401,445 0.4%
Susquehanna International Group, LLP Private Company 2026/Q4 +328,899 0.4%
Jupiter Fund Management Plc Mutual Fund 2026/Q4 +252,030 0.2%
Logos Global Management, L.P. Hedge Fund 2026/Q4 +250,000 0.2%
Deka Investment GmbH Mutual Fund 2026/Q4 +246,868 0.4%
Victory Capital Management Inc. Mutual Fund 2026/Q4 +218,607 0.8%
Bank of America Corporation Public Company 2026/Q4 +207,872 0.4%
ZKB Asset Management Mutual Fund 2026/Q4 +201,784 0.3%
Deep Track Capital, LP VC/PE Fund 2026/Q4 +200,000 0.2%
Capital Impact Advisors, LLC Mutual Fund 2026/Q4 +184,025 0.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
9 Nov 2026 Sanjay Keswani Former Chief Medical Officer Intent to Sell (Form 144) -53,614 $167.37 –
3 Nov 2026 Eiry Roberts Chief Medical Officer Other Derivative Acquisition +1,506 – 1,506
3 Nov 2026 Eiry Roberts Chief Medical Officer Other Derivative Acquisition +8,314 $166.05 8,314
2 Nov 2026 George Morrow Independent Director Derivative Exercise and Sale -15,000 $168.53 10,386
31 Oct 2026 Kyle Gano Chief Executive Officer Derivative Exercise and Sale -332 $146.10 155,010
31 Oct 2026 Kyle Gano Chief Executive Officer Derivative Exercise and Retained +282 – 155,010
27 Sep 2026 Eiry Roberts Chief Medical Officer Initial Statement of Beneficial +0 – 16,129
13 Sep 2026 Matthew Abernethy Chief Financial Officer Automatic Disposition -2,311 $157.20 42,808
13 Sep 2026 David Boyer Chief Corporate Affairs Officer Automatic Disposition -826 $157.45 8,722
10 Sep 2026 Kevin Gorman Director Sale to Issuer -7,839 $156.22 517,797
10 Sep 2026 Kevin Gorman Director Other Acquisition +14,343 – 517,797
10 Sep 2026 Julie Cooke Chief Human Resources Officer Sale to Issuer -1,936 $156.22 24,025
10 Sep 2026 Julie Cooke Chief Human Resources Officer Other Acquisition +3,587 – 24,025
10 Sep 2026 Eric Benevich Chief Commercial Officer Sale to Issuer -3,386 $156.22 67,297
10 Sep 2026 Eric Benevich Chief Commercial Officer Other Acquisition +6,275 – 67,297
10 Sep 2026 Jude Onyia Chief Scientific Officer Sale to Issuer -1,936 $156.22 22,647
10 Sep 2026 Jude Onyia Chief Scientific Officer Other Acquisition +3,587 – 22,647
10 Sep 2026 Darin Lippoldt Chief Legal Officer Sale to Issuer -2,419 $156.22 56,793
10 Sep 2026 Darin Lippoldt Chief Legal Officer Other Acquisition +4,483 – 56,793
10 Sep 2026 Kyle Gano Chief Executive Officer Sale to Issuer -4,380 $156.22 154,728

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 5,900,825 5.8% 5.4
15 Oct 2026 6,447,491 6.3% 4.5
30 Sep 2026 5,853,128 5.8% 4.0
15 Sep 2026 4,964,907 4.9% 5.4
31 Aug 2026 5,056,144 5.0% 4.7
14 Aug 2026 4,551,075 4.5% 3.4

Discussion

No comments yet — be the first to weigh in on NBIX.

Sign in to join the discussion.

Scroll to Top